DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical…
| Price | $6.86 |
|---|---|
| Market cap | $369.64M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 5.245-10.4195 |
| Beta | 0.97 |
Explore DMAC's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.